Trial Profile
A Phase 2 Randomized, Double-blind, Placebo-controlled Study in HLA-DQ2.5+ Adults With Celiac Disease to Assess the Effect of Nexvax2 on Symptoms After Masked Gluten Food Challenge
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs HLA DQ2 peptide vaccine (Primary)
- Indications Coeliac disease
- Focus Proof of concept; Therapeutic Use
- Acronyms RESET CeD
- Sponsors ImmusanT
- 25 Jun 2019 Results published in an ImmusanT media release.
- 25 Jun 2019 According to an ImmusanT media release, the company discontinued this trial as the results from an interim analysis revealed Nexvax2 did not provide statistically meaningful protection from gluten exposure for celiac disease patients when compared with placebo.
- 25 Jun 2019 Status changed from active, no longer recruiting to discontinued, according to an ImmusanT media release.